Replimune's RP1 Shows Durable 3-Year Survival in Advanced Melanoma
REPL has more than doubled off its 52-week low of $1.5 on elevated volume (7.4× avg).
Summary
Replimune presented strong 3-year overall survival data for its lead candidate RP1 in anti-PD-1-failed advanced melanoma at the ASCO meeting. The data showed a median overall survival of 32.9 months, with 47.8% of all treated patients alive at three years, and 83.5% of responders. This positive long-term efficacy data provides significant support for RP1, especially following the recent agreement with the FDA to resubmit its Biologics License Application. The durable benefit in this difficult-to-treat patient population is crucial for the drug's potential approval and commercial viability.
At the time of this announcement, REPL was trading at $8.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $717.6M. The 52-week trading range was $1.50 to $13.24. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.